Skip to content

ImmunityBio, Inc. IBRX Return on equity

Discontinued — last reported Q3 '20

Return on equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
38.8%+7.3pp
Johnson & Johnson logo
Johnson & JohnsonJNJ
26.4%-3.0pp
Merck & Co. logo
Merck & Co.MRK
19%-20.3pp
Gilead Sciences logo
Gilead SciencesGILD
43.2%+10.7pp
Summit Therapeutics logo
Summit TherapeuticsSMMT
-271%-1,725pp
Incyte logo
IncyteINCY
30.8%+30.4pp

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$7.71B+208%
Enterprise value$7.95B+187%
P/S54.7×-25.4×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Debt / equity0.1×
Current ratio6.7×+4.4×

Where this comes from

Calculated from ImmunityBio, Inc.’s reported figures.

Based on trailing twelve months.

The official record: ImmunityBio, Inc.’s 10-Q, filed November 12, 2021, on SEC EDGAR. View the filing →

Questions, answered.

What does return on equity mean?
How much profit the company earns on the money shareholders have invested.
How do you interpret return on equity?
Higher is better, but very high ROE can be manufactured by leverage — a thin equity base inflates the ratio. Read it next to debt-to-equity and ROIC to tell genuine returns from balance-sheet engineering.
How does return on equity compare across companies?
Comparable across peers, with the leverage caveat. Negative or near-zero equity makes ROE meaningless, so it is suppressed there.